HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Timothy C Zhu Selected Research

motexafin lutetium (Lutrin)

8/2008Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
5/2007Quantitative comparison of tissue oxygen and motexafin lutetium uptake by ex vivo and noninvasive in vivo techniques in patients with intraperitoneal carcinomatosis.
9/2006Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
1/2006Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
3/2002In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
1/2002In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Timothy C Zhu Research Topics

Disease

42Neoplasms (Cancer)
01/2022 - 03/2002
17Fibrosarcoma
08/2020 - 03/2014
9Necrosis
11/2016 - 02/2009
7Malignant Mesothelioma
01/2020 - 03/2015
6Mesothelioma
06/2020 - 02/2012
6Prostatic Neoplasms (Prostate Cancer)
02/2015 - 06/2005
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2014 - 01/2006
4Body Weight (Weight, Body)
02/2013 - 01/2006
4Pleural Effusion (Pleural Effusions)
02/2013 - 01/2006
3Carcinoma (Carcinomatosis)
03/2018 - 05/2007
2Peritoneal Neoplasms
01/2020 - 01/2005
2Skin Neoplasms (Skin Cancer)
03/2011 - 01/2004
2Hypoxia (Hypoxemia)
12/2009 - 05/2007
1Carcinoma in Situ
03/2018
1Breast Neoplasms (Breast Cancer)
01/2002

Drug/Important Bio-Agent (IBA)

531-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2022 - 01/2002
16Photosensitizing Agents (Photosensitizers)IBA
08/2020 - 03/2002
15Singlet OxygenIBA
01/2020 - 02/2009
12Dihematoporphyrin Ether (Porfimer Sodium)FDA Link
01/2022 - 01/2005
8Oxygen (Dioxygen)IBA
06/2020 - 01/2006
82-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH)IBA
12/2016 - 03/2010
6Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 02/2018
6Pharmaceutical PreparationsIBA
01/2020 - 06/2005
6motexafin lutetium (Lutrin)IBA
08/2008 - 01/2002
2Protons (Proton)IBA
01/2019 - 07/2015
2Verteporfin (Visudyne)FDA Link
01/2017 - 03/2015
2Cytotoxins (Cytolysins)IBA
02/2012 - 02/2009
1AcidsIBA
03/2018
1ElementsIBA
02/2016
1pyropheophorbide aIBA
03/2015
1temoporfinIBA
02/2015
1Hematoxylin (Haematoxylon)IBA
03/2014
1Eosine Yellowish-(YS) (Eosin)IBA
03/2014
1Prostate-Specific Antigen (Semenogelase)IBA
08/2008
1acetamideIBA
05/2007
1Hemoglobins (Hemoglobin)IBA
01/2006
1Dronabinol (THC)FDA LinkGeneric
01/2005

Therapy/Procedure

39Photochemotherapy (Photodynamic Therapy)
01/2022 - 01/2002
5Lasers (Laser)
01/2017 - 01/2006
3Therapeutics
03/2021 - 01/2019
3Radiotherapy
01/2019 - 01/2006
3Aftercare (After-Treatment)
02/2018 - 01/2006
1Proton Therapy
01/2019
1Phototherapy (Light Therapy)
02/2013
1Complementary Therapies (Alternative Medicine)
03/2011
1Brachytherapy
03/2011